Helix Biopharma Corp (HBPCF) 1.3902 $HBPCF Heli
Post# of 273382
Posted On: 09/15/2016 5:02:36 AM
Helix Biopharma Corp (HBPCF) 1.3902 $HBPCF
Helix Biopharma Corp. to Present at Precision Lung Cancer World R&D Summit
Marketwire Canada - Fri Sep 09, 6:45AM CDT
Therapeutic Strategy Against Tumor Acidity Induced Immune-Suppression: L-DOS47 a Clinical Candidate for Lung Cancer
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Announces New Director Appointment
Marketwire Canada - Wed Sep 07, 6:45AM CDT
AURORA, ON--(Marketwired - Sep 7, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"
, an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announces the appointment of Dr. Theordore J. Witek, Jr. to the board of directors of Helix.
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11), INVA: 11.45 (+0.14)
Helix BioPharma Corp. Announces CAR-T Poster Presentation at the AACR Conference
Marketwire Canada - Thu Sep 01, 6:30AM CDT
CAR-T Cells Harboring Camelid Single Domain Antibody as Targeting Agent to CEACAM6 Antigen in Pancreatic Cancer
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Closes CAD1.8 Million Private Placement
Marketwired - Fri Jul 29, 3:01PM CDT
AURORA, ON--(Marketwired - Jul 29, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company", an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD1.8 million.
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Appoints Evolution Life Science Partners as Advisors
Marketwired - Thu Jun 02, 7:00AM CDT
AURORA, ON--(Marketwired - Jun 2, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company", a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Evolution Life Science Partners to act as advisors to the Company. Activities the Company may pursue could include, but are not limited to, partnering or other collaboration agreements. The Company does not intend to disclose developments with respect to this process except as required under applicable securities regulations.
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
First Patient Dosed in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Wed May 11, 6:30AM CDT
AURORA, ON--(Marketwired - May 11, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company", a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient was dosed in the Phase II component of study LDOS002.
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Subsidiary, Helix Polska Sp zo.o., Qualifies for CAD4.1 Million Grant From the Polish National Center for Research and Development
Marketwire Canada - Mon May 09, 6:30AM CDT
AURORA, ON--(Marketwired - May 9, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company", a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its wholly owned subsidiary, Helix Polska Sp. z o.o. qualifies for a grant of approximately PLN12.5mil from the Polish National Centre for Research and Development to develop V-DOS47 in breast cancer. The acceptance of the grant is subject to review and approval of the final terms and conditions by Helix's management and Board of Directors and may be subject to conditions imposed by the granting authority and corporate or other approvals.
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Closes CAD4.7 Million Private Placement Financing
Marketwired - Fri Apr 29, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company", a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD4.7 million.
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
First Patient Enrolled in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 28, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company", a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient has been enrolled in the Phase II component of study LDOS002.
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Trial Steering Committee Recommends Initiation of Phase II L-DOS47 Study in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 21, 4:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company", a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recommendation by the Trial Steering Committee to initiate the Phase II component of the LDOS002 study.
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Announces Important Additions to Its Leadership Team
Marketwire Canada - Wed Apr 20, 6:30PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company", a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Dr. Patrick Frankham to Chief Operating Officer and the promotion of Mr. Steve Demas to the position of Chief Medical Officer. Dr. Frankham and Mr. Demas will both report directly to Dr. Sven Rohmann, Helix's newly appointed Chief Executive Officer.
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix Biopharma Corp. to Present at Precision Lung Cancer World R&D Summit
Marketwire Canada - Fri Sep 09, 6:45AM CDT
Therapeutic Strategy Against Tumor Acidity Induced Immune-Suppression: L-DOS47 a Clinical Candidate for Lung Cancer
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Announces New Director Appointment
Marketwire Canada - Wed Sep 07, 6:45AM CDT
AURORA, ON--(Marketwired - Sep 7, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"
, an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, announces the appointment of Dr. Theordore J. Witek, Jr. to the board of directors of Helix. HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11), INVA: 11.45 (+0.14)
Helix BioPharma Corp. Announces CAR-T Poster Presentation at the AACR Conference
Marketwire Canada - Thu Sep 01, 6:30AM CDT
CAR-T Cells Harboring Camelid Single Domain Antibody as Targeting Agent to CEACAM6 Antigen in Pancreatic Cancer
HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Closes CAD1.8 Million Private Placement
Marketwired - Fri Jul 29, 3:01PM CDT
AURORA, ON--(Marketwired - Jul 29, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"
, an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD1.8 million. HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Appoints Evolution Life Science Partners as Advisors
Marketwired - Thu Jun 02, 7:00AM CDT
AURORA, ON--(Marketwired - Jun 2, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"
, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Evolution Life Science Partners to act as advisors to the Company. Activities the Company may pursue could include, but are not limited to, partnering or other collaboration agreements. The Company does not intend to disclose developments with respect to this process except as required under applicable securities regulations. HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
First Patient Dosed in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Wed May 11, 6:30AM CDT
AURORA, ON--(Marketwired - May 11, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"
, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient was dosed in the Phase II component of study LDOS002. HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Subsidiary, Helix Polska Sp zo.o., Qualifies for CAD4.1 Million Grant From the Polish National Center for Research and Development
Marketwire Canada - Mon May 09, 6:30AM CDT
AURORA, ON--(Marketwired - May 9, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"
, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its wholly owned subsidiary, Helix Polska Sp. z o.o. qualifies for a grant of approximately PLN12.5mil from the Polish National Centre for Research and Development to develop V-DOS47 in breast cancer. The acceptance of the grant is subject to review and approval of the final terms and conditions by Helix's management and Board of Directors and may be subject to conditions imposed by the granting authority and corporate or other approvals. HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Closes CAD4.7 Million Private Placement Financing
Marketwired - Fri Apr 29, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"
, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD4.7 million. HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
First Patient Enrolled in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 28, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"
, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient has been enrolled in the Phase II component of study LDOS002. HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Trial Steering Committee Recommends Initiation of Phase II L-DOS47 Study in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 21, 4:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"
, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recommendation by the Trial Steering Committee to initiate the Phase II component of the LDOS002 study. HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
Helix BioPharma Corp. Announces Important Additions to Its Leadership Team
Marketwire Canada - Wed Apr 20, 6:30PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"
, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Dr. Patrick Frankham to Chief Operating Officer and the promotion of Mr. Steve Demas to the position of Chief Medical Officer. Dr. Frankham and Mr. Demas will both report directly to Dr. Sven Rohmann, Helix's newly appointed Chief Executive Officer. HBP: 5.90 (+0.08), HBP.TO: 1.90 (+0.11)
(0)
(0)